anti-gb3 monoclonal antibody inhibits angiogenesis and tumor developmentanti-gb3单克隆抗体抑制血管生成和肿瘤的发展.pdf

Anti-Gb3 Monoclonal Antibody Inhibits Angiogenesis and Tumor Development 1,2,3. 1,2,3. ´ ` 1,2,3,4 1,2,3 Ariane Desselle , Tanguy Chaumette , Marie-Helene Gaugler , Denis Cochonneau , 1,2,3 1,2,3,6 5 1,2,3 ´ ´ 1,2,3 Julien Fleurence , Nolwenn Dubois , Philippe Hulin , Jacques Aubry , Stephane Birkle , Franc¸ois Paris1,2,3,6* ´ 1 Inserm, UMR892, Nantes, France, 2 Universite de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France, 3 CNRS, UMR 6299, Nantes, France, 4 Institut ˆ ´ ´ ´ ´ de Radioprotection et de Surete Nucleaire, Fontenay-aux-Roses, France, 5 Inserm, SFR Sante UMS 016, Nantes, France, 6 Institut de Cancerologie de l’Ouest, Saint-Herblain, France Abstract Inhibiting the growth of tumor vasculature represents one of the relevant strategies against tumor progression. Between all the different pro-angiogenic molecular targets, plasma membrane glycosphingolipids have been under-investigated. In this present study, we explore the anti-angiogenic therapeutic advantage of a tumor immunotherapy targeting the globotriaosylceramide Gb3. In this purpose, a monoclonal antibody against Gb3, named 3E2 was developed and characterized. We first demonstrate that Gb3 is over-expressed in proliferative endothelial ce